Aralez finally gets an FDA OK for its cardio drug Yosprala, starts hiring sales reps
The third time proved the charm for Aralez Pharmaceuticals. After two years of back and forth with the FDA over a serious manufacturing snafu, the agency has finally given its thumbs up to the biotech’s cardio drug Yosprala.
The approval clears the way for the Canadian company to add 85 sales reps to its commercialization arm. Yosprala is approved for “patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.